PT2402002T - Composições de 1,2,4-oxadiazole oralmente activo para terapia de supressão de mutações nonsense - Google Patents
Composições de 1,2,4-oxadiazole oralmente activo para terapia de supressão de mutações nonsenseInfo
- Publication number
- PT2402002T PT2402002T PT11175569T PT11175569T PT2402002T PT 2402002 T PT2402002 T PT 2402002T PT 11175569 T PT11175569 T PT 11175569T PT 11175569 T PT11175569 T PT 11175569T PT 2402002 T PT2402002 T PT 2402002T
- Authority
- PT
- Portugal
- Prior art keywords
- oxadiazole
- compositions
- stop codon
- diseases associated
- treating diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66978905P | 2005-04-08 | 2005-04-08 | |
US78739506P | 2006-03-30 | 2006-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2402002T true PT2402002T (pt) | 2018-10-08 |
Family
ID=36763092
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT11175569T PT2402002T (pt) | 2005-04-08 | 2006-04-06 | Composições de 1,2,4-oxadiazole oralmente activo para terapia de supressão de mutações nonsense |
PT06749439T PT1874306E (pt) | 2005-04-08 | 2006-04-06 | Composições de um 1,2,4-oxadiazole oralmente activo para terapia de supressão de mutações sem sentido (ou nonsense) |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT06749439T PT1874306E (pt) | 2005-04-08 | 2006-04-06 | Composições de um 1,2,4-oxadiazole oralmente activo para terapia de supressão de mutações sem sentido (ou nonsense) |
Country Status (17)
Country | Link |
---|---|
US (7) | US8716321B2 (pt) |
EP (2) | EP1874306B1 (pt) |
JP (3) | JP5800451B2 (pt) |
CN (1) | CN103720688A (pt) |
AU (1) | AU2006235115C1 (pt) |
BR (1) | BRPI0609089A2 (pt) |
CA (1) | CA2603402C (pt) |
DK (2) | DK2402002T3 (pt) |
ES (2) | ES2683359T3 (pt) |
HK (1) | HK1111897A1 (pt) |
IL (2) | IL186433A (pt) |
MX (1) | MX2007012206A (pt) |
NO (2) | NO339909B1 (pt) |
NZ (1) | NZ562197A (pt) |
PL (2) | PL1874306T3 (pt) |
PT (2) | PT2402002T (pt) |
WO (1) | WO2006110483A1 (pt) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3889142T (pt) * | 2003-04-11 | 2022-08-22 | Ptc Therapeutics Inc | Compostos de ácido 1,2,4-oxodiazolobenzoico e sua utilização para a supressão sem sentido e o tratamento de doenças |
US8716321B2 (en) | 2005-04-08 | 2014-05-06 | Ptc Therapeutics, Inc. | Methods for dosing an orally active 1,2,4-oxadiazole |
NZ596965A (en) | 2006-03-30 | 2013-06-28 | Ptc Therapeutics Inc | Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith |
MX2008012945A (es) | 2006-04-07 | 2009-01-15 | Vertex Pharma | Moduladores de transportadores de cartucho de union a adenosina-trifosfato celular (atp). |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
MY148598A (en) * | 2006-09-08 | 2013-05-15 | Ptc Therapeutics Inc | Processes for the preparation of 1,2,4-oxadiazole benzoic acids |
WO2008130370A1 (en) | 2006-09-25 | 2008-10-30 | Ptc Therapeutics, Inc. | Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression |
ES2655338T3 (es) | 2006-09-25 | 2018-02-19 | Ptc Therapeutics, Inc. | Procedimiento de preparación de formas cristalinas del ácido 3-[5-(2-fluorofenil)-[1,2,4]-oxadiazol-3-il]-benzoico |
AU2016262645B2 (en) * | 2006-10-12 | 2018-05-17 | Ptc Therapeutics, Inc. | Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
JP2010506840A (ja) | 2006-10-12 | 2010-03-04 | ピーティーシー セラピューティクス,インコーポレーテッド | ナンセンス突然変異抑制治療用の経口的に活性な1,2,4−オキサジアゾールの投与方法 |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
ES2617957T3 (es) | 2007-08-03 | 2017-06-20 | Summit (Oxford) Limited | Combinaciones farmacológicas para el tratamiento de la distrofia muscular de Duchenne |
NZ585980A (en) | 2007-11-16 | 2012-04-27 | Vertex Pharma | Isoquinoline modulators of atp-binding cassette transporters |
CA2706920C (en) | 2007-12-07 | 2018-02-13 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
CA2718310C (en) | 2008-03-31 | 2018-08-07 | Vertex Pharmaceuticals Incorporated | Pyridyl derivatives as cftr modulators |
NZ700556A (en) | 2010-03-25 | 2016-04-29 | Vertex Pharma | Solid forms of (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
HRP20211752T1 (hr) | 2010-04-07 | 2022-02-18 | Vertex Pharmaceuticals Incorporated | Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena |
TWI549950B (zh) | 2010-04-07 | 2016-09-21 | 維泰克斯製藥公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]二氧雜環戊烯-5-基)環丙烷甲醯胺基)-3-甲基吡啶-2-基)苯甲酸之固體形式 |
SG10201505700QA (en) | 2010-04-22 | 2015-08-28 | Vertex Pharma | Process of producing cycloalkylcarboxamido-indole compounds |
US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
ES2710854T3 (es) | 2010-08-05 | 2019-04-29 | Univ Lille | Compuesto útil para el tratamiento de enfermedades mediadas por una mutación sin sentido y composición farmacéutica que comprende dicho compuesto |
BR112013004443A8 (pt) | 2010-08-23 | 2018-01-02 | Vertex Pharma | composições farmacêuticas de (r)-1-(2,2-difluorbenzo[d] [1,3]dioxol-5-il)-n-(1-(2,3-di-hidróxipropil)-6-flúor-2-(1-hidróxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropano carboxamida e administração das mesmas |
MX357328B (es) | 2011-11-08 | 2018-07-05 | Vertex Pharma | Moduladores de trasportadores de casete enlazante de atp. |
CA2862859C (en) | 2012-01-25 | 2022-08-02 | Vertex Pharmaceuticals Incorporated | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
US9012496B2 (en) | 2012-07-16 | 2015-04-21 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof |
RS57831B2 (sr) | 2012-11-02 | 2024-02-29 | Vertex Pharma | Farmaceutske kompozicije za lečenje bolesti posredovanih sa cftr |
WO2014153643A1 (en) * | 2013-03-26 | 2014-10-02 | The University Of British Columbia | Compositions and methods for use thereof in the treatment of aniridia |
CA3174516A1 (en) | 2014-03-06 | 2015-09-11 | Ptc Therapeutics, Inc. | Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid |
SI3131582T1 (sl) | 2014-04-15 | 2018-09-28 | Vertex Pharmaceuticals Incorporated | Farmacevtski sestavki za zdravljenje bolezni, pri katerih posreduje regulator transmembranske prevodnosti |
WO2015188037A1 (en) * | 2014-06-06 | 2015-12-10 | Ptc Therapeutics, Inc. | Methods of treatment using a 1,2,4-oxadiazole benzoic acid |
EP3798214B1 (en) | 2014-10-06 | 2022-09-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
KR20180081516A (ko) | 2015-10-30 | 2018-07-16 | 피티씨 테라퓨틱스, 인크. | 간질 치료 방법 |
US10898483B2 (en) | 2015-12-23 | 2021-01-26 | Moonshot Pharma Llc | Methods for inducing an immune response by promoting premature termination codon read-through |
TW201808922A (zh) * | 2016-06-20 | 2018-03-16 | 台灣神隆股份有限公司 | 製備阿塔魯仁及其中間體的方法 |
EP3512516A1 (en) | 2016-09-13 | 2019-07-24 | Marco Cipolli | Method of treatment of shwachman-diamond syndrome |
WO2018237326A1 (en) | 2017-06-22 | 2018-12-27 | 1AlMOONSHOT PHARMA LLC | METHODS OF TREATING CANCER USING COMPOSITIONS COMPRISING AMLEXANOX AND IMMUNOMODULATORS |
CA3079833A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Bridged bicyclic compounds as farnesoid x receptor modulators |
EP3713934B1 (en) | 2017-11-23 | 2022-04-13 | Universita' degli Studi di Palermo | Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations |
US20220071965A1 (en) | 2018-12-20 | 2022-03-10 | Pfizer Inc. | Pharmaceutical Compositions and Methods Comprising A Combination of a Benzoxazole Transthyretin Stabilizer and an Additional Therapeutic Agent |
KR20210129119A (ko) | 2019-02-15 | 2021-10-27 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서 유용한 치환된 아미드 화합물 |
CN113727973A (zh) | 2019-02-15 | 2021-11-30 | 百时美施贵宝公司 | 可用作类法尼醇x受体调节剂的取代酰胺化合物 |
WO2020168148A1 (en) | 2019-02-15 | 2020-08-20 | Bristol-Myers Squibb Company | Substituted bicyclic compounds as farnesoid x receptor modulators |
AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
WO2022112919A1 (en) | 2020-11-25 | 2022-06-02 | Pfizer Inc. | (aza)benzothiazolyl substituted pyrazole compounds |
WO2023121199A1 (ko) * | 2021-12-21 | 2023-06-29 | 재단법인 아산사회복지재단 | 신경섬유종증의 치료적 및 진단적 타겟으로서의 활성화된 ras 및 그의 용도 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY128323A (en) * | 1996-09-30 | 2007-01-31 | Otsuka Pharma Co Ltd | Thiazole derivatives for inhibition of cytokine production and of cell adhesion |
FI107732B (fi) * | 1998-03-18 | 2001-09-28 | Xyrofin Oy | Laktitolin kiteyttäminen, kiteinen laktitolituote ja sen käyttö |
US6660753B2 (en) * | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
US6316029B1 (en) * | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
JP2005504014A (ja) * | 2001-06-08 | 2005-02-10 | サイトビア インコーポレイテッド | カスパーゼの活性化因子およびアポトーシスの誘導因子としての置換された3−アリール−5−アリール−[1,2,4]−オキサジアゾール類および類似体、並びにその使用法 |
MY151199A (en) * | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
NZ538339A (en) * | 2002-08-09 | 2007-01-26 | Astrazeneca Ab | Oxadiazoles as modulators of metabotropic glutamate receptor-5 |
US20040253307A1 (en) * | 2003-02-04 | 2004-12-16 | Brian Hague | Sugar-free oral transmucosal solid dosage forms and uses thereof |
GB0303503D0 (en) * | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
PT3889142T (pt) * | 2003-04-11 | 2022-08-22 | Ptc Therapeutics Inc | Compostos de ácido 1,2,4-oxodiazolobenzoico e sua utilização para a supressão sem sentido e o tratamento de doenças |
WO2004110351A2 (en) * | 2003-05-14 | 2004-12-23 | Anadys Pharmaceuticals, Inc. | Heterocyclic compounds for treating hepatitis c virus |
US8716321B2 (en) | 2005-04-08 | 2014-05-06 | Ptc Therapeutics, Inc. | Methods for dosing an orally active 1,2,4-oxadiazole |
US20070010553A1 (en) * | 2005-07-01 | 2007-01-11 | Astrazeneca Ab | New use |
MY148598A (en) | 2006-09-08 | 2013-05-15 | Ptc Therapeutics Inc | Processes for the preparation of 1,2,4-oxadiazole benzoic acids |
ES2655338T3 (es) * | 2006-09-25 | 2018-02-19 | Ptc Therapeutics, Inc. | Procedimiento de preparación de formas cristalinas del ácido 3-[5-(2-fluorofenil)-[1,2,4]-oxadiazol-3-il]-benzoico |
CA3174516A1 (en) | 2014-03-06 | 2015-09-11 | Ptc Therapeutics, Inc. | Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid |
-
2006
- 2006-04-06 US US11/918,114 patent/US8716321B2/en active Active
- 2006-04-06 PT PT11175569T patent/PT2402002T/pt unknown
- 2006-04-06 AU AU2006235115A patent/AU2006235115C1/en active Active
- 2006-04-06 PL PL06749439T patent/PL1874306T3/pl unknown
- 2006-04-06 ES ES11175569.0T patent/ES2683359T3/es active Active
- 2006-04-06 PT PT06749439T patent/PT1874306E/pt unknown
- 2006-04-06 PL PL11175569T patent/PL2402002T3/pl unknown
- 2006-04-06 WO PCT/US2006/012887 patent/WO2006110483A1/en active Application Filing
- 2006-04-06 MX MX2007012206A patent/MX2007012206A/es active IP Right Grant
- 2006-04-06 DK DK11175569.0T patent/DK2402002T3/en active
- 2006-04-06 ES ES06749439T patent/ES2390804T3/es active Active
- 2006-04-06 DK DK06749439.3T patent/DK1874306T3/da active
- 2006-04-06 CA CA2603402A patent/CA2603402C/en active Active
- 2006-04-06 BR BRPI0609089-3A patent/BRPI0609089A2/pt not_active Application Discontinuation
- 2006-04-06 EP EP06749439A patent/EP1874306B1/en active Active
- 2006-04-06 JP JP2008505534A patent/JP5800451B2/ja active Active
- 2006-04-06 EP EP11175569.0A patent/EP2402002B1/en active Active
- 2006-04-06 NZ NZ562197A patent/NZ562197A/en unknown
- 2006-04-06 CN CN201310655012.3A patent/CN103720688A/zh active Pending
-
2007
- 2007-10-07 IL IL186433A patent/IL186433A/en active IP Right Grant
- 2007-11-07 NO NO20075682A patent/NO339909B1/no unknown
-
2008
- 2008-06-17 HK HK08106626.1A patent/HK1111897A1/xx unknown
-
2013
- 2013-06-04 JP JP2013117678A patent/JP5808367B2/ja active Active
-
2014
- 2014-03-21 US US14/221,352 patent/US9474743B2/en active Active
- 2014-12-30 IL IL236518A patent/IL236518B/en active IP Right Grant
-
2015
- 2015-07-06 JP JP2015134950A patent/JP2015212292A/ja active Pending
-
2016
- 2016-10-12 US US15/291,173 patent/US10034863B2/en active Active
-
2017
- 2017-01-09 NO NO20170035A patent/NO340617B1/no unknown
-
2018
- 2018-06-28 US US16/021,419 patent/US10285980B2/en active Active
-
2019
- 2019-03-29 US US16/368,992 patent/US10675272B2/en active Active
-
2020
- 2020-05-05 US US16/866,822 patent/US11497736B2/en active Active
-
2022
- 2022-10-11 US US17/963,838 patent/US20230218587A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2402002T3 (pl) | Kompozycje zawierające kwas 1,2,4-oksadiazolobenzoesowy i ich zastosowania do leczenia chorób związanych z przedwczesnym kodonem stop | |
IL250858B (en) | A tetracycline compound, a pharmaceutical composition comprising the tetracycline compound, and the tetracycline compound or the pharmaceutical composition for treating a tetracycline responsive state | |
IL188602A0 (en) | Non-flammable insecticide composition and uses thereof | |
IL195580A (en) | L – fkbp polypeptides, preparations containing them, methods of preparation and use | |
IL190874A0 (en) | 1h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof | |
ZA200707353B (en) | 4-cyclopropyl-1,2,3-thiadiazole compound, agrohorticultural plant disease controlling agent and method of using the same | |
PL1859004T3 (pl) | Środki sieciujące kompozycję opracowania odwiertu oraz ich zastosowania | |
HK1123972A1 (zh) | 乙酰半胱氨酸組合物及其用途 | |
PL1951838T3 (pl) | Kompozycje zawierające fluoroolefiny i ich zastosowania | |
ZA200802777B (en) | Safety needle with lockout mechanism | |
EP1991218A4 (en) | USE OF CYCLOLIGNANS IN THE TREATMENT OF TYPE 2 DIABETES AND AS CONTRACEPTIVES | |
HK1128487A1 (en) | Compositions comprising fluoroolefins and uses thereof | |
ZA200901132B (en) | Human GLP-1 mimetibodies, compositions, methods and uses | |
PT1693027E (pt) | Ponta de facoemulsificação | |
EP2103653A4 (en) | COMPOSITION AND LIGHT-EMITTING ELEMENT COMPRISING THE COMPOSITION | |
IL178166A0 (en) | 1,3,4-oxadiazol-2-ones as ppar delta | |
EP1828305A4 (en) | LOW LOSS PREIMPREGNE, COMPOSITIONS USEFUL FOR ITS PREPARATION AND USES THEREOF | |
EP1866044A4 (en) | COMPOSITION | |
HUE043668T2 (hu) | Szemészeti készítmények és alkalmazásuk | |
IL178259A0 (en) | Novel benzothiazoles and the use thereof as medicaments | |
ZA200903935B (en) | Novel arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use | |
EP1991059A4 (en) | INSECTICIDAL COMPOSITIONS AND USES THEREOF | |
EP2088140A4 (en) | DIHYDRAZIDE COMPOUNDS, MANUFACTURE AND APPLICATIONS THEREOF | |
IL188787A (en) | Preparations for the treatment of diabetic eye complications | |
ZA200802784B (en) | Assembly for presenting and preparing a puffed composition |